Shaanxi Xiyue Pharmaceutical Co Ltd.

Primary objective: Using febuxostat tablets (trade name: Feburic, specification: 40 mg) from Teijin Pharma Limited as the reference preparation and febuxostat tablets (40 mg) developed by Shaanxi Xiyue Pharmaceutical Co., Ltd. as the test preparation, a single-center, randomized, open, single-dose, two-preparation, two-cycle, two-sequence, crossover clinical trial was conducted to evaluate the bioequivalence of the two preparations in fasting and fed states in healthy Chinese subjects. Secondary objective: To observe the safety of the test preparation and reference preparation in healthy Chinese subjects.

Primary objective: To investigate the pharmacokinetic parameters and relative bioavailability of celecoxib capsules (0.2 g) manufactured by Shaanxi Xiyue Pharmaceutical Co., Ltd. as the test formulation and celecoxib capsules (trade name: Celebrex®, 0.2 g) manufactured by Viatris Pharmaceuticals LLC as the reference formulation after a single fasting administration, and to evaluate the bioequivalence of the two formulations. Secondary objective: To evaluate the safety of a single fasting oral administration of celecoxib capsules (test and reference formulations) to participants in the Chinese Health Study.

Primary objective: To investigate the pharmacokinetic parameters and relative bioavailability of celecoxib capsules (0.2 g) manufactured by Shaanxi Xiyue Pharmaceutical Co., Ltd. as the test formulation and celecoxib capsules (trade name: Celebrex®, 0.2 g) manufactured by Viatris Pharmaceuticals LLC as the reference formulation after a single postprandial dose, and to evaluate the bioequivalence of the two formulations. Secondary objective: To evaluate the safety of single postprandial oral administration of celecoxib capsules (test and reference formulations) in participants of the Chinese Health Study.